Crispr Therapeutics AG (NASDAQ:CRSP) – Oppenheimer cut their Q1 2020 earnings per share estimates for shares of Crispr Therapeutics in a report issued on Monday, November 25th. Oppenheimer analyst S. Tuerkcan now forecasts that the company will post earnings of ($0.89) per share for the quarter, down from their previous forecast of ($0.87). Oppenheimer has a “Outperform” rating and a $80.00 price target on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million.
Several other research analysts also recently commented on CRSP. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Goldman Sachs Group raised their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Chardan Capital restated a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Canaccord Genuity raised their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research report on Wednesday, November 20th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $69.54.
Shares of NASDAQ:CRSP opened at $68.11 on Thursday. The firm’s 50 day moving average is $48.67 and its two-hundred day moving average is $45.94. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The firm has a market capitalization of $3.63 billion, a P/E ratio of -19.80 and a beta of 3.15. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. boosted its position in Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares in the last quarter. ARK Investment Management LLC grew its holdings in shares of Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Orbimed Advisors LLC purchased a new position in shares of Crispr Therapeutics during the third quarter worth about $21,167,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Why do corrections happen?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.